ANGIOSOMA Share Price OTC Markets

Equities

SOAN

US03476L1026

Biotechnology & Medical Research

End-of-day quote OTC Markets 23:00:00 04/02/2024 GMT 5-day change 1st Jan Change
0.0009 USD -.--% Intraday chart for ANGIOSOMA +20.00% -.--%
Sales 2022 - Sales 2023 - Capitalization 1.79M 142M
Net income 2022 -1M -79.08M Net income 2023 -1M -79.08M EV / Sales 2022 -
Net Debt 2022 152K 12.05M Net Debt 2023 366K 28.94M EV / Sales 2023 -
P/E ratio 2022
-1.56 x
P/E ratio 2023
-0.76 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 92.42%
More Fundamentals * Assessed data
Dynamic Chart
GlobeStar Therapeutics Corporation (GlobeStar Therapeutics) is a clinical-stage pharmaceutical company. The Company is focused on introducing a patented formulation of drugs for the treatment of Multiple Sclerosis and other neurodegenerative diseases. The Company owns the global license from the inventors, who are based in Italy. The Company has acquired a license for a patented method of treating neurodegenerative diseases such as Multiple Sclerosis by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration and treating neurodegeneration. GlobeStar Therapeutics is initiating discussions with the Food and Drug Administration (FDA) on clinical trial design in preparation for FDA submission and approval pathway.
More about the company